Session » Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1564

Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease

1:00PM-3:00PM: Abstract Number: 1572

CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis

1:00PM-3:00PM: Abstract Number: 1575

Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis

1:00PM-3:00PM: Abstract Number: 1576

Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis

1:00PM-3:00PM: Abstract Number: 1563

Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Incomplete Behçet’s Disease

1:00PM-3:00PM: Abstract Number: 1555

Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study

1:00PM-3:00PM: Abstract Number: 1571

Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort

1:00PM-3:00PM: Abstract Number: 1561

Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

1:00PM-3:00PM: Abstract Number: 1565

Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease

1:00PM-3:00PM: Abstract Number: 1556

Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease

1:00PM-3:00PM: Abstract Number: 1553

Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 1547

Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica

1:00PM-3:00PM: Abstract Number: 1568

Evaluation for Allogeneic Hematopoietic Stem Cell Transplant Indications and Eligibility in a Prospective Cohort of Patients with VEXAS

1:00PM-3:00PM: Abstract Number: 1548

Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients

1:00PM-3:00PM: Abstract Number: 1577

Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life

1:00PM-3:00PM: Abstract Number: 1545

Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica

1:00PM-3:00PM: Abstract Number: 1550

Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis

1:00PM-3:00PM: Abstract Number: 1544

Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica

1:00PM-3:00PM: Abstract Number: 1559

Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines

1:00PM-3:00PM: Abstract Number: 1578

Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis

1:00PM-3:00PM: Abstract Number: 1569

Lung Involvement in VEXAS Syndrome

1:00PM-3:00PM: Abstract Number: 1570

Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning

1:00PM-3:00PM: Abstract Number: 1557

Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center

1:00PM-3:00PM: Abstract Number: 1560

Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease

1:00PM-3:00PM: Abstract Number: 1566

Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 1558

Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain

1:00PM-3:00PM: Abstract Number: 1552

Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis

1:00PM-3:00PM: Abstract Number: 1567

Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol

1:00PM-3:00PM: Abstract Number: 1543

Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR

1:00PM-3:00PM: Abstract Number: 1554

Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis

1:00PM-3:00PM: Abstract Number: 1551

The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis

1:00PM-3:00PM: Abstract Number: 1549

Toward Safer Glucocorticoid Therapy

1:00PM-3:00PM: Abstract Number: 1546

Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry

1:00PM-3:00PM: Abstract Number: 1562

Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification

1:00PM-3:00PM: Abstract Number: 1574

Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System

1:00PM-3:00PM: Abstract Number: 1573

Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis

« View all sessions from this meeting